Tempus AI Earnings Call Highlights Growth and Scale
Tempus AI reported Q3 revenue of $412M, up 23% YoY. Diagnostics and oncology revenues grew 20% and 28%, respectively. The company highlighted major collaborations with BMS, Moderna, and Merck, and expects positive adjusted EBITDA. Management acknowledged reimbursement risks and Personalis' current losses but remains optimistic about growth opportunities, including a $20B MRD market.
How this was made
The 30-second read
Why it matters
The recap reinforces prior expectations but provides no actionable insight.
Market read
The article is a post‑earnings summary with no new data; limited trading relevance.
What to watch
None; all material points were covered in the original earnings release.
Background
Tempus AI reported 23% revenue growth and positive adjusted EBITDA for Q3, with several partnership announcements.
Ticker impact
The article recaps Tempus AI's Q3 earnings call, repeating revenue and EBITDA figures already released 13 days earlier.
likely flat as market has priced the earnings already.
All financial metrics were disclosed in the prior earnings release; the article adds no fresh information.
Market effects
None; the biotech data‑analytics sector sees no new development.
None; US market already incorporated the earnings.
Low
Counterpoint
No contrarian angle; the story offers no new upside or downside.
Key entities
- CompanyTempus AI, Inc.
Provider of data and AI services for oncology and other health areas.


